Clinical Trials Logo
  1. Home
  2. Chemotherapeutic Toxicity
  3. NCT06357871

Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer — NEPHROTOX  

Chemotherapeutic Toxicity Clinical Trial

Official title:
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer

Clinical Trial Summary

Checkpoint inhibitors represent a new class of widely used immunotherapy, however with immune-mediated adverse effects, with renal damage estimated at 1.4% and 4.9% depending on the series. Acute tubulointerstitial nephritis (ATNI) represents the most common type of damage, although there are other types of damage, associated or not with NTIA. We aim to establish a probability score for the presence of histological NTIA lesions in a patient treated with CPI who presents with acute renal failure in order to guide the nephrologist and oncologist in their management in the event of AKI at the CPI, and determine the usefulness of a PBR to guide the suspension/resumption of immunotherapy +/- associated corticosteroid therapy; avoiding a PBR exposing to a high iatrogenic risk and sometimes impossible.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06357871
Study type Observational
Source Central Hospital, Nancy, France
Contact Adrien Flahault, MD, PhD
Phone +33 3 83 15 31 69
Email a.flahault@chru-nancy.fr
Status Recruiting
Phase
Start date November 28, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04277650 - System for High-Intensity Evaluation During Radiotherapy N/A
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT06012253 - The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life N/A
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Recruiting NCT06197581 - Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer N/A
Not yet recruiting NCT04965532 - Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia N/A
Completed NCT04843410 - Effect of Exercise in the Management of Peripheral Neuropathy N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Terminated NCT04607668 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Phase 3
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Completed NCT00292526 - Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients Phase 4
Completed NCT04663178 - Foot Bath and Chemotherapy Induced Fatigue N/A
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT05251922 - Tolerance of Anti-Cancer Therapy in the Elderly
Not yet recruiting NCT06387901 - Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
Recruiting NCT05892146 - Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction N/A
Not yet recruiting NCT05921149 - Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT05302336 - AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer Phase 4